Physician profile
Todd Wechter
NPI 1699235192
$943.50
in general payments reported to CMS, 2019-2025
14 companies · $611 in 2025
The $611 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $254 · 2024: $79.08 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.77 | 2023-2025 | |
| Dermavant Sciences, INC. | $172.22 | 2023 | Vtama |
| Janssen Biotech, INC. | $138.58 | 2025 | Tremfya |
| Ucb, INC. | $74.57 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $51.82 | 2025 | |
| Amgen INC. | $43.67 | 2023-2025 | Amjevita, Otezla |
| Sun Pharmaceutical Industries INC. | $37.45 | 2025 | |
| Genzyme Corporation | $34.97 | 2025 | |
| Leo Pharma INC. | $20.74 | 2024 | Adbry |
| Biofrontera INC. | $20.41 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $17.62 | 2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $17.18 | 2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $16.83 | 2025 | Zoryve |
| Pfizer INC. | $14.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Wechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.